Compare F5 Inc (FFIV) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
F5 Inc vs Inovio Pharmaceuticals Inc — how do they compare? F5 Inc trades at $421.52 (market cap $23.44B), while Inovio Pharmaceuticals Inc trades at $0.76 (market cap $78.55M). The key difference: F5 Inc is far larger — about 298.4× Inovio Pharmaceuticals Inc's market cap, and F5 Inc is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| FFIV | INO | |
|---|---|---|
Market Cap | $23.44B | $78.55M |
Sector | Technology | Health |
52-Week High | $431.26 | $2.87 |
52-Week Low | $223.99 | $0.66 |
Enterprise Value | $22.08B | $49.56M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
F5 (FFIV) stock trades at $417.70, up 1.88% with bullish technical signals and strong earnings beats. Recent Q3 2026 results showed EPS of $4.73 versus $4.00 expected, driven by 19% product revenue growth. The company raised its fiscal outlook, reflecting robust demand for application security and AI infrastructure. Key support lies at $411, with resistance at $422.
Outlook remains positive due to consistent earnings outperformance and raised guidance, though valuation multiples like P/E of 32.98 suggest premium pricing. Risks include competitive pressures and reliance on enterprise spending cycles. Analyst consensus price target of $430.43 implies moderate upside potential from current levels.
INO trades at $0.76, up 2.74% today, but remains in a bearish technical trend. The company shows minimal revenue of $65K against high operating losses, with a net income margin of -130,000%. Recent quarterly EPS has beaten expectations. Analyst consensus is bullish with a $3.25 price target, but the stock faces significant fundamental challenges including negative cash flow and high valuation multiples.
The outlook hinges on FDA approval of INO-3107 in October 2026, a binary event that could drive substantial upside. However, persistent cash burn, negative profitability, and ongoing shareholder litigation present high risks. Investors should weigh the potential catalyst against the company's weak financial health and operational execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About F5 Inc
F5 is a market leader in the application delivery controller market. The company sells products for networking traffic, security, and policy management. Its products ensure applications are safely routed in efficient manners within on-premises data centers and across cloud environments. More than half of its revenue is based on providing services, and its three customer verticals are enterprises, service providers, and government entities. The Seattle-based firm was incorporated in 1996 and generates sales globally.
Read more on FFIV →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
